INTRODUCTION eight women received pretreatment with gestogen, and a similar number of women received pretreatment with the pill. The flare protocol was used in all treatment cycles
The success of in vitro fertilization and embryo transfer combined with an individualized dose of human menopausal (IVF-ET) is closely related to controlled ovarian hypergonadotropin (hMG) (4) (5) (6) (7) (8) 4, prevalence of low responders is up to 18% according respectively). There also was no difference seen in the numto the definitions used (3) .
bers of oocytes retrieved (4.4 Ϯ 2.3 vs. 4.2 Ϯ 2.5), total
The definition of a low responder is controversial.
number of embryos (2.5 Ϯ 2.4 vs. 2.2 Ϯ 1.1), or the number
There has been an abundance of criteria to identify low responders prior to COH, initially including advanced age Ͼ37 years (4), prior ovarian surgery (5), and women who, in previous COH, required markedly plasma follicle-stimulating hormone (FSH) and estra-diol levels can predict those with poor response to for pretreatment with hormonal preparation, i.e., COH irrespective of age (7, 8) . Others have introduced medroxyprogestrone acetate (gestogen) or oral contravarious dynamic tests to further identify low respondceptive pill (OCP) based on the attending physician's ers, such as the clomiphene citrate challenge test (9, 10) , choice. Initially, gestogen was used to facilitate cycle gonadotropin challenge test, and gonadotropin-releasprograms, but was prescribed subsequently as pretreating hormone analogue (GnRHa) test (11) . More ment. The OCP was considered an option for pretreatrecently, other tests to identify low response have been ment more recently. Typically, OCP was given to start reported, such as measuring inhibin (12) and ultrasonofrom day 4 of the menstrual cycle for minimum of 21 graphic ovarian volume measurement and examining days to a maximum of 42 days, while the gestogen the number of small follicles present before ovarian tablets were typically given at a dose of 10 mg twice stimulation (13) (14) (15) . A universally accepted definition a day from day 15 of the cycle preceding the IVF of low responders certainly is not available; neverthetreatment for a period of 2-3 weeks. All patients had less, early follicular plasma FSH levels remain the an ultrasound scan 1 week before completing their most widely used test to predict a response to COH tablets to exclude the presence of large ovarian cysts. and identify patients with limited ovarian reserve (16).
The patients were advised to stop the tablets, await Pretreatment with oral contraceptive pills before withdrawal bleeding, and start the gonadotropincommencing COH is reported to improve the ovarian releasing hormone analogue (Nafarelin acetate 200 g response (17,18). Pretreatment with progestogen has per nostril twice a day; Synarel, Searle Pharmaceutical been claimed to improve IVF outcome generally (19) .
Products, England) on the second day of the period. There are many COH protocols for low responders
The hMG dosage was individualized based on the reporting varying degrees of success (20) . We describe previous response to COH, the early follicular phase our experience in 76 patients who were considered to serum FSH, age, and body mass index (BMI). A starting be low responders to COH by one or more of the dose of 4-8 ampoules (75 IU FSH/ampoule) based on above criteria following the use of a gestogen, medroxthe criteria mentioned was started on the same day as yprogesterone acetate (Provera, Pharmacia, and the GnRHa. Monitoring of the ovarian response was Upjohn, England) and an oral contraceptive pill (Marvelon, Organon, England) in the cycle preceding the performed by regular vaginal ultrasonography and IVF treatment.
human chorionic gonadotropin (hCG) 10,000 IU (Profasi; Serono, England) was administered when one or more leading follicles measuring Ͼ18 mm in diameter and an endometrial thickness Ն8 mm were seen. Both
MATERIALS AND METHODS
hMG injections and GnRHa were continued until the time of hCG administration. Cycles were abandoned if, A total of 76 [IVF ϭ 61; intracytoplasmic sperm after 10 days of COH, less than four mature follicles injection (ICS) ϭ 15] cycles were included in this (Ն 14 mm) were seen on ultrasonography. Transvaginal nonrandomized, retrospective, observational study. ultrasound-guided oocyte retrieval was performed 34-Women having one or more of the following criteria 36 hr after the hCG trigger injection, in 61 cycles stanwere included: (1) a previous abandoned cycle followdard in vitro insemination was conducted and in 15 ing a standard COH protocol because of a very low cycles, ICSI. A maximum of three embryos were transresponse (fewer than three follicles Ͼ14 mm after ferred into the uterus 2 or 3 days after oocyte retrieval, 10-12 days of stimulation); (2) fewer than four oocytes and luteal support with vaginal pessaries containing 400 retrieved following a standard COH protocol; (3) early mg of progesterone was continued daily for at least 2 follicular phase (days 2-4 of cycle) serum FSH Ͼ8 weeks after embryo transfer (ET). If pregnancy was IU/liter; and (4) women aged Ͼ39 years. The majority determined 2 weeks after ET, ultrasound was performed of women had more than one of the above inclusion to confirm the presence of intrauterine pregnancy typicriteria. Ovum donation was discussed with all patients cally 5 weeks after ET. who had a low response in previous cycles, were Ͼ40
The Student's t test was used to compare the statistiyears old, and had high serum FSH. All patients cal significance of samples in the different group. The included had early follicular phase FSH, luteinizing chi square exact probability test was used to compare hormone (LH) and estradiol (E 2 ) plasma levels meapercentages observed. Statistical significance was sured within 3 months before treatment. As the availability of donor oocytes is poor, patients were selected defined as P Ͻ 0.05. One pregnancy was ers. There were no statistically significant differences seen in any of the parameters studied between the two achieved in each group resulting in live births at term. groups (Table I) . Table II summarizes the outcome of the most recent IVF cycle in 63 patients who had previous treatment. Thirty-seven women (58.7%) DISCUSSION reached oocyte retrieval and ET, while in 26 women (41.3%) the cycle was abandoned due to lack of or very This study examined the possible beneficial effect low ovarian response. In the remaining 13 patients, the in low responders of two preparations of synthetic study cycle was their first IVF treatment.
steroids followed by a "flare" protocol of COH. There The COH characteristics of the study patients are was no difference seen between the two groups with described in Table III . There were no statistically sigrespect to their age, duration of infertility, early follicunificant differences seen in mean number of ampoules lar phase FSH levels, or the cause of infertility. Both of hMG used, the number of cycles abandoned, the groups consisted of patients with the worst prognosis mean number of oocytes collected, the number of total in our IVF program. A significantly higher dose of embryos available (as an indication of fertilization and hMG was used in the index cycle of treatment when cleavage), and number of embryos transferred (Table  compared to the previous treatment cycle in those III). Although a larger amount of hMG was used in women who had previous IVF (64.4 Ϯ 25.5 vs. 53 Ϯ the gestogen group than the OCP, this difference was 21.7; P ϭ 0.007). Despite this increase in hMG dose, not statistically significant [95% confidence interval the number of oocytes retrieved and the number of (CI): Ϫ0.87 to 21.87; P ϭ 0.07]. A statistically sigembryos generated did not show a corresponding rise. The rate of abandoned cycles was lower in the study cycle, but this was not statistically significant (38.2% pointingly, the pregnancy rate was very low (2.6%) in follicles. The use of the OCP in our study to suppress both groups, and for that reason we discontinued the serum FSH did not support this concept. whole trial. A weakness in this study is the lack of Karande and colleagues (25) recently reported their a control group. As this was an observational study experience with the "flare" protocol in low responders, examining clinical practice, we did not use a control describing an adequate ovarian response but a low group because our purpose was to try to determine ongoing pregnancy rate (6.5% per retrieval). Their whether either protocol would improve the outcome study differed from ours in that they selected a group of these poor responder patients.
with an elevated day-3 FSH Ͼ12 IU/liter or a history Improving pregnancy rates in low responders of poor response and they only started the COH when remains one of the biggest challenges that faces the day-2 FSH was Յ 12 IU/liter in the treatment cycle. assisted conception treatment (21). The low pregnancy
The poor outcome in their study (6.5% pregnancy rate rate in this group was mainly attributed to serious per retrieval) confirmed that patients with a history of oocyte factors. Previous studies have shown a favorelevated basal FSH do poorly with such subsequent able effect of the "flare" protocol in low responders stimulation (26). Our data expand on this information (11, 22 ) and pretreatment cycle with estrogen (23) and and confirm that using OCP or gestogen, which will the use of the oral contraceptive pill before commenclower the basal FSH, apparently does not improve the ing COH (11, 18) presumably by eliminating the exisclinical outcome in low responders. Our findings also tence of the corpus luteum, suppressing endogenous support other earlier reports that concluded that FSH to normal, and restoring the sensitivity in the increasing the hMG dose does not improve the prognoovarian follicle to exogenous FSH. Pretreatment with sis (3, 27) . Increasing the dose of gonadotropin may progestogen, apart from aiding in timing the start of produce some benefits, but the saturation kinetic is COH, has been reported to improve IVF outcome in reached as no further benefit was gained from further general, probably through a similar mechanism to increase. The total hMG dose in the gestogen group estrogen pretreatment (19) . IVF cycle pretreatment was higher than in the OCP group by a mean total with progesterone is characterized by reduced gonadonumber of 10 ampoules (750 IU) possibly as a result tropin flare-up response, no increase in corpus luteum of decrease in flare effect in pretreatment with gestogen rescue by GnRHa, and identical pregnancy rate to (24). But, despite this increase, the stimulation and cycles without pretreatment (24). The reduced gonadopregnancy outcome remained very low. Increasing the tropin flare-up response to GnRHa may be a factor in dose to more than 450 IU per day of FSH does not the high hMG dose and the poor overall response in improve follicular recruitment or the pregnancy rate the gestogen group and very possibly may explain the in low responders (28). As follicular recruitment starts same outcome in the OCP group. Keay and colleagues before the index cycle by an unspecified time interval, (20) suggested that by suppressing serum FSH to norRombauts and colleagues (29) commenced the gonadmal, and hence down-regulating the ovarian FSH receptors, sensitivity may be restored in the remaining otropin stimulation in the luteal phase in women with suboptimal ovarian stimulation, but this strategy also protocol, GnRHa luteal phase down-regulation is initiated, then discontinued with the start of the menses did not improve the outcome.
The dose of GnRHa required to maintain pituitary and COH initiation on day 3 of the cycle. In 224 cycles, there was a 12.5% cancellation rate and only one suppression decreased with increasing length of treatment (30) . By using a smaller dose of short-acting patient had a premature LH surge; a respectable 28% pregnancy rate per attempt was achieved in these low GnRHa (Triptorelin or leuprolide) to produce pituitary suppression; further reducing the dose at the start of responders (39). A decrease in ovarian volume measured by transva-COH produced better results for low responders (31) (32) (33) . The flare-up regimen of GnRHa protocol is associginal sonography (TVS) was reported to be associated with poor response to ovarian stimulation (40). The ated with early elevated level of progesterone due to corpus luteum rescue (34) . Oral contraceptive and gesnumber of small ovarian follicles (2-5 mm) detected by TVS after GnRHa and before COH was reported togen pretreatment can reduce the effect. The combination of oral contraceptive pretreatment and microdose to give better prediction of number of oocytes retrieved than the woman's age or ovarian volume (15). If these GnRHa in a flare-up protocol has been reported to result in a higher estrogen peak, more mature oocytes, findings are further confirmed and shown to be closely related to other ovarian reserve tests, surely they will and increased numbers of embryos available for transfer (35) .
lead to less costly and more easily accessible tests. The decline in ovarian reserve leads to a decline in Schoolcraft and colleagues (36) have examined the use of growth hormone as showing possible benefit to reproductive potential. Even those with normal FSH but who do not respond to hMG stimulation are COH in low responders. In this study, pretreatment with OCP and the flare protocol with microdose reported to be at risk of developing ovarian failure within several months (41). The decline in ovarian GnRHa was used in conjunction with growth hormone, but the selection of patients differed from our study response is due to an ovarian or intraovarian cause. This decline could be influenced by genetic factors, and others (3, 27) . The study also employed embryoassisted hatching techniques. The evidence on the surgical treatment (as ovarian or pelvic surgery), endometriosis, or immunological factors. Our group also value of growth hormone remains controversial (22, 37, 38) . The value of microdose GnRHa though is has confirmed that cigarette smoking can adversely affect ovarian reserve (42) . worthy of consideration in larger studies. The pretreatment of each cycle with oral contraceptive pill before Oocyte donation is the ultimate treatment for women who repeatedly fail to adequately respond to COH. In commencing COH (17,18) presumably by eliminating the existence of the corpus luteum and so preventing our experience, women are reluctant to take this option early in their fertility treatment. Furthermore, the legal the progesterone rise in the early follicular stage and suppressing endogenous FSH to normal will restore restrictions on oocyte donation in Great Britain (i.e., no payment of donors) has resulted in a very long the sensitivity in the ovarian follicle to exogenous FSH. Pretreatment with progestogen apart from aiding in waiting list for anonymous oocyte donation and almost complete of known donation. Pressure is then placed timing the start of COH has been reported to improve IVF outcome in general, probably through a similar on couples and on their fertility specialists to try other options in the hope of successful pregnancy with the mechanism to estrogen pretreatment (19) . Pretreatment with progesterone was confirmed to eliminate corpus full knowledge that some of these treatment options result in very low pregnancy. luteum rescue and progesterone rise, but it has been characterized by a reduced GnRHa flare-up and did
We conclude that, as the pregnancy rate remained very low in women who are identified as low respondnot improve pregnancy rate (24).
The mechanism and the site of action of GnRHa is ers when using pretreatment OCP or gestogen in a flare protocol associated with a high gonadotropin dose, this at several levels and is partly unknown. Following down-regulation, there may be residual gonadotropin strategy should not be used for this purpose. As the low responders group is very heterogeneous, managesecretion, depending on hypophyseal sensitization, and this may depend on the GnRHa protocol and which ment is difficult and needs to be individualized, and oocyte donation needs to be considered with the couple particular analogue is used. GnRHa also may affect the ovary directly and the endometrium receptivity.
as an option if low response to COH is combined with other indicators of low ovarian reserve. More These concerns may explain the emergence of the microdose GnRHa protocol and the earlier cessation experience and research into alternative treatment strategies need to be considered urgently in these cases after down-regulation protocol (39). In the "cessation" 
